Definium’s $805M offering leads follow-on quartet: Public Equity Report

Led by Definium’s $805 million follow-on, a handful of biopharmas raised nine-digit sums this week after turning over data cards that induced investors to fund their next steps in the clinic.

A Phase III readout in major depressive disorder that lifted shares of psychedelic neuroscience company  Definium Therapeutics Inc. (NASDAQ:DFTX) by 50% on Monday opened the door to a follow-on. The company proposed after the bell to raise $500 million. It priced a $700 million offering late Tuesday, and when its underwriters exercised their greenshoe option in full, Definium closed the offering at $805 million Thursday night...